Document is current

Article History

Received: 25 October 2023

Accepted: 15 January 2024

First Online: 24 January 2024

Declarations

:

: The Institutional Review Boards at Aminu Kano Teaching Hospital, Murtala Mohammed Specialist Hospital, and Vanderbilt University Medical Center approved the SAMS trial. The study included participants exclusively below the age of 16, and their legal guardians granted written informed consent prior to screening and enrollment. Moreover, children aged seven and above also provided assent alongside their guardians’ consent.

: Not applicable.

: Dr. DeBaun and his institution sponsor two externally funded research investigator-initiated projects. Clinical studies will have funds provided by Global Blood Therapeutics (GBT). GBT was not a co-sponsor of either study. Dr. DeBaun did not receive any compensation for the conduct of these two investigator-initiated observational studies. Dr. DeBaun is a member of the GBT advisory board for a proposed randomized controlled trial for which he receives compensation. Dr. DeBaun is on the steering committee for a Novartis-sponsored phase II trial to prevent priapism in men. Dr. DeBaun was a medical advisor in developing the CTX001 Early Economic Model and provided medical input as part of an expert reference group for the Vertex/CRIPR CTX001 Early Economic Model in 2020. Dr. DeBaun consulted for the Formal Pharmaceutical company about sickle cell disease in 2021 and 2022. The authors have no other relevant affiliation or financial involvement with any entity or organization with a financial interest in or conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.